

Billing and Coding Guide

Your Access and Reimbursement Manager:					
Name:					
Phone: Em	ail:				
With just a call or click, you can get assistance from a dedicated IZERVAY My Way SM Access Coordinator.					
Phone: 1-888-C5MYWAY (1-888-256-9929) 8 AM to 8 PM ET Monday - Friday	Fax: 1-833-C5MYWAY (1-833-256-9929)				
Email: Support@IZERVAYMyWay.com	Website: IZERVAYecp.com/PatientSupport				

This Billing and Coding Guide is for general informational purposes only. The codes listed reflect a sample of potentially relevant codes but the provider is responsible for selecting the appropriate diagnosis, procedure, and billing codes that truthfully reflect the diagnosis and level of service provided to the patient in each instance of administration of IZERVAY.

The information in this guide is subject to change without notice and should be verified by the provider for each patient prior to treatment. Contact the patient's health plan directly for the most accurate information.

Astellas Pharma US, Inc. does not guarantee payment or coverage for any product or service.

Codes for billing and reimbursement

The codes below are common codes that may be used when filing a claim for IZERVAY. For the most accurate codes, please contact your patient's health plan.

Current Procedural Terminology (CPT®) codes for imaging¹		
CPT code	Description	
92134	Optical coherence tomography	
92235	Fluorescein angiography (FA)	
92250	Fundus photography (Fundus autofluorescence)	
92240	Indocyanine green angiography (ICG)	
92242	FA and ICG	

CPT code for injections ²				
CPT code	Site modifier	Description		
67028	Apply the appropriate site modifier (LT, RT, or 50) to the end of CPT code 67028	Intravitreal injection		

LT, left eye; RT, right eye; 50, both eyes.

CPT* codes and descriptions are © 2025 American Medical Association (AMA). All rights reserved.

References: 1. Centers for Medicare & Medicaid Services. Physician fee schedule search. Accessed January 9, 2025. https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=0&HT=1&CT=0&H1=92134&H2=92235&H3=92250&H4=92240&H5=92242&M=1 **2.** Medicare.gov. Intravitreal injection of a pharmacologic agent (separate procedure). Accessed January 9, 2025. https://www.medicare.gov/procedure-price-lookup/cost/67028

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.



Evaluation and management (E/M) codes ¹		
CPT code	Description	
99203	New Patient Level 3 E/M	
99213	Established Patient Level 3 E/M	
99204	New Patient Level 4 E/M	
99214	Established Patient Level 4 E/M	

Other E/M codes may apply or be more appropriate for a given visit. Please refer to the E/M coding and documentation guidelines in the CPT book provided by the American Medical Association.


Office visit modifi	er ²
Modifier	Description
25	Significant, separately identifiable evaluation and management service by the same physician or other qualified healthcare professional on the same day of the procedure or other services.

Office visit modifiers help with prompt and correct payment based on evaluation and management services provided. These modifiers do not apply to services like tests or surgeries.

References: 1. Centers for Medicare & Medicaid Services. Physician fee schedule search. Accessed January 9, 2025. https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=0&HT=1&CT=0&H1=99203&H2=99213&H3=99204&H4=99214&M=1 **2.** American Academy of Ophthalmology. Effectively use exam modifiers. Accessed January 9, 2025. https://www.aao.org/young-ophthalmologists/yo-info/article/effectively-use-exam-modifiers

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.







Check with the patient's health plan to determine sequence requirements regarding the use of a 10-digit or 11-digit NDC as it may vary.

References: 1. Centers for Medicare and Medicaid Services. ICD-10. Accessed January 10, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes#CodeFiles **2.** Izervay. Package insert. Northbrook, IL: Astellas Pharma US, Inc. **3.** Chun J. Format of the National Drug Code. Accessed January 10, 2025. https://www.fda.gov/media/173715/download

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.



Healthcare Common Procedure Coding System (HCPCS) code ¹				
HCPCS	code	escriptor	Site of care	Billing units*
J278		vacincaptad pegol al solution, 0.1 mg	All sites of care	20

When using the permanent J-code, bill 20 units for a 2-mg dose of IZERVAY.* Be sure to check with each payer for specific coding requirements.

*One billing unit of J2782 equals 0.1 mg of avacincaptad pegol. As a result, billing for 20 units equals a 2-mg dose of IZERVAY.¹

JZ modifier: Effective July 1, 2023, providers and suppliers are required to report the JZ modifier on all claims that bill for drugs from single-dose containers that are separately payable under Medicare Part B when there are no discarded amounts.²

Important reminders when billing for IZERVAY

Ensure the following information is included in the claim submission:

- Drug name/generic name
- Strength
- Unit administered
- Route of administration
- NDC
- Appropriate codes (ICD-10, CPT, HCPCS)

Some health plans may also request the following:

- Prescribing information
- FDA approval letter
- Any relevant documentation to support medical necessity (EHR documentation, letter of medical necessity, etc)
- Drug purchase invoice

References: 1. Centers for Medicare & Medicaid Services. CMS HCPCS Application Summaries and Coding Recommendations: Fourth Quarter, 2023 HCPCS Coding Cycle. Accessed January 9, 2025. https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-4-2023-drugs-and-biologicals-updated-04/25/2024.pdf **2.** Centers for Medicare & Medicaid Services. Medicare program: discarded drugs and biologicals-JW modifier and JZ modifier policy frequently asked questions. Accessed January 9, 2025. https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-fags.pdf


It is your responsibility to ensure that claim forms are completed accurately based on the clinical visit.

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.



Sample CMS-1500 form

The sample claim form below is just an example of how services provided in a physician's office may be billed on the CMS-1500 form.



Reference: 1. Centers for Medicare & Medicaid Services. Medicare program: discarded drugs and biologicals–JW modifier and JZ modifier policy frequently asked questions. Accessed January 9, 2025. https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf


It is your responsibility to ensure that claim forms are completed accurately based on the clinical visit.

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.



Sample CMS-1450 form

The sample claim form below is just an example of how services provided in a hospital outpatient department may be billed on the CMS-1450 form.



References: 1. Noridian Healthcare Solutions. Revenue codes. Accessed January 9, 2025. https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes **2.** Centers for Medicare & Medicaid Services. Medicare program: discarded drugs and biologicals-JW modifier and JZ modifier policy frequently asked questions. Accessed January 9, 2025. https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf

It is your responsibility to ensure that claim forms are completed accurately based on the clinical visit.

It is always the provider's responsibility to determine the appropriate clinical diagnosis and healthcare setting to submit true and accurate claims for the products and services rendered.



INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

 IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

- Endophthalmitis and Retinal Detachments
 - Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Neovascular AMD
 - In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
- Increase in Intraocular Pressure
 - Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

 Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

Please see full <u>Prescribing Information</u> for more information.





Wherever you are in the process, we are ready to provide access and reimbursement support for IZERVAY.

With just a call or click, you can get assistance from a dedicated IZERVAY My WaySM Access Coordinator.







Website: IZERVAYecp.com/PatientSupport

It is always the provider's responsibility to determine the appropriate codes for the products and services rendered. Astellas Pharma US, Inc. does not guarantee payment or coverage for any product or service.

